A study by scientists at Imperial College London has revealed that antibodies against COVID-19 declined rapidly in the British population during the summer, suggesting protection after infection may not be long lasting and raising the prospect of waning immunity in the community, Reuters news agency reported on Tuesday.
Imperial College London scientists have tracked antibody levels in the British population following the first wave of COVID-19 infections in March and April 2020. The study found that antibody prevalence fell from 6% of the population around the end of June to just 4.4% in September 2020. That raises the prospect of decreasing population immunity ahead of a second wave of infections that has forced local lockdowns and restrictions in recent weeks.
According to the researchers, although immunity to COVID-19 is a complex and murky area and may be assisted by T cells, as well as B cells that can stimulate the quick production of antibodies following re-exposure to the virus, the experience of other coronaviruses suggested immunity might not be enduring.
Wendy Barclay, Head of Department of Infectious Disease at Imperial College London was quoted as telling reporters: "We can see the antibodies and we can see them declining and we know that antibodies on their own are quite protective. On the balance of evidence I would say, with what we know for other coronaviruses, it would look as if immunity declines away at the same rate as antibodies decline away, and that this is an indication of waning immunity at the population level."
Reportedly, those whose COVID-19 was confirmed with a gold standard PCR test had a less pronounced decline in antibodies, as compared to people who had been asymptomatic and unaware of their original infection. Also, there was no change in the levels of antibodies seen in healthcare workers, possibly due to repeated exposure to the virus.
Imperial's findings were released as a pre-print paper and have not yet been peer-reviewed.
Barclay said that the rapid waning of antibodies from infection did not necessarily have implications for the efficacy of vaccine candidates currently in clinical trials, adding, "A good vaccine may well be better than natural immunity."
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial